Many scientific papers deal with the distribution of ß-thalassemia mutations in Arab populations. As a consequence, knowledge of this subject has been widely scattered, and access to the information is beyond the capacity of the individual investigator. Thus, Deniz (http://biobase.fatih.edu.tr/), an integrating electronic database, was established to prevent references to outdated data and to condense all information into clear trends and facts. The database currently includes data on ß-thalassemia mutations from 14 Arab countries, but the design and structure allow the addition of future data. According to the Deniz database, six mutations are responsible for 66.2% of the Arab ß-thalassemia chromosomes. Other applications are the prediction of diagnostic strategies that may be offered to natives of unstudied countries and provision of insights into the origins of ß-thalassemia in the Arab world. Integration of Deniz with other databases is currently in process.
Comments
Both the HbVar and Deniz databases try to make (integrated) genetic information available for health care workers. HbVar recently expanded with frequency distribution data, and Deniz focuses on this kind of data by definition. As mentioned by Patrinos et al., such information significantly simplifies mutation analysis. Tadmouri and Gulen also mention the application of Deniz in the prediction of diagnostic strategies. Another potential field of use would be in effectuating genetic screening programs for hemoglobinopathies. Hemoglobinopathies are recessive inherited disorders. Screening programs aim to detect carrier couples of a mutation in the hemoglobin genes to inform them about the risk of having an affected child. Such programs are currently utilized in some countries with a high prevalence of hemoglobinopathies (for example Italy, Greece and Cyprus) [3] . To assess the properties of a database for use in clinical and population screening applications, it is important to evaluate database design and content, sources of data and accessibility [4] .
Both databases deal with frequency distribution data of ß-thalassemia mutations. The available information may be useful in a screening program, because it provides the ability to start genetic screening of most frequently occurring mutations in the relevant ethnic background. This is particularly valuable in countries with many different ethnic groups at risk. However, screening of ß-thalassemia mutations is not enough to inform an individual about the risk of an affected newborn. Other mutations in the hemoglobin genes are also able to induce a major ß-thalassemia phenotype. An example is the compound heterozygote combination of HbE and a ß-thalassemia mutation, which is very common in Southeast Asia. Consequently, a screening program must include many variants of hemoglobinopathies, and therefore a database with distribution frequency data for all types of hemoglobinopathy mutations would be more helpful.
Other useful data would be the phenotype which belongs to a specific genotype. This information is needed to fully inform the individual undergoing screening about the severity of the disease. HbVar tries to include these data (unfortunately, knowledge about the geno-type-phenotype correlation is not always that clear). Tadmouri and Gulen do not mention this feature of the Deniz database explicitly.
The World Wide Web has made it possible to provide both databases to a widespread community, so accessibility is not a problem. However, with the existence of databases containing more or less the same information, the user does not always know which one to access. The user can compare databases according to his/her own needs, and it may be possible that competition between databases could lead to optimization of their quality. On the other hand, it takes a lot of effort for the potential user to assess the databases in the correct way. Besides, the quality of a database may change over time, depending on the frequency of updating. All similar databases have to be updated with the same new information. This means, therefore, a lot of construction work. In conclusion, the existence of two more or less similar databases is not efficient. However, with the existence of only one database, the user must totally rely on that specific one. To guarantee quality of 'The hemoglobinopathy database', an option is to ask for financial contributions, which can be used to increase quality control. Both publications discussed herein mention intentions to work on greater integration of databases, so perhaps setting up one comprehensive database is possible?
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Understanding Why Negative Genetic Test Results Sometimes Fail to Reassure
Predictive genetic testing enables people at risk for inherited conditions to learn about their chance of developing the condition. Where early intervention is effective, clinical surveillance or treatment can be implemented. Some of the first studies, however, suggested that there might be problems in compliance with surveillance amongst those individuals with positive test results, whereas others reported problems of the desire for unwarranted clinical surveillance amongst those individuals receiving negative test results. In the paper of Michie et al., it is discussed why some people apparently are not reassured by receiving a negative genetic test result.
In an earlier quantitative study of 127 people receiving negative test results following familial adenomatous polyposis testing, it was found that 42% expected to attend future bowel cancer screening [1] . The main predictor of wanting to continue to attend for bowel screening was doubt about the accuracy of the genetic test. There is, however, little research investigating how people think about screening and diagnostic tests and what psychological impact they may have. The aim of the study of Michie et al. was to gain greater understanding of how people represent the genetic test and the genetic basis of the condition in order to explain why some desire to continue with clinically unnecessary screening. The study employed a quantitative method, 'interpretative phenomenological analyses', which has been used to study a wide range of topics concerning psychological aspects of new genetics. Nine patients who received negative results following predictive testing for familial adenomatous polyposis within the previous year at a London hospital were interviewed. Five of them felt no need for future bowel or fecal screening; four expressed a desire for future screening.
The results of the study show that the reasons for not feeling reassured by the negative genetic test results could be divided into two main categories: (1) perceptions of the genetic basis of the condition: the dominantly inherited condition could be caused by a new spontaneously arising mutation, or caused by other factors in addition to genes; (2) perceptions of the genetic test: a blood test was either not represented as genetic or was seen as insignificant since it was not related to the part of the body in which the potential problem would occur.
The authors suggest that eliciting and, when appropriate, changing people's representations prior to testing may enable those receiving negative results to be more reassured about their residual risk.
Comments
This paper shows the unfamiliarity of lay people with genetic testing. Genetic tests might therefore be perceived as less reliable and/or less reassuring than they should be based on a medical perspective. The findings in this paper are therefore of great interest to all who work in the field of (clinical) genetics or in the field of informing the population on genetics. Besides changing people's representations prior to testing, more general information about genetic testing provided to the population at large is needed in order to ensure that genetic test results will be perceived as reliable and become as reassuring as they should be.
However, there might also be other reasons why some patients are not reassured by negative genetic test results and perceive a continuing risk for themselves and their children. In a study of hereditary non-polyposis colorectal cancer, McAllister [2] found that family members who were offered a predictive test for hereditary non-polyposis colorectal cancer had very fixed ideas about what the result(s) of the test(s) would be, and that these beliefs might affect adjustment to predictive test results. Accordingly, some patients might still feel at risk for the disease, despite a negative test result. Moreover, in that study [2] , patients were told during the pretest consultation that a negative test result is a guarantee that they will not develop polyposis, but that they still had the same risk as the general population of developing bowel cancer. Since these patients are familiar with this specific kind of cancer, they might be more afraid of it than the gener-al population. It is known that individuals with a family history of cancer commonly overestimate their risk of developing cancer [3] , even if they understand that the risk is small. This can be explained in terms of the availability heuristic, i.e. the tendency for an event (e.g. disease) to be judged more probable to the extent that it is more easily pictured or recalled. Peay and Peay [4] found that in particular for symptoms that might be indicative of cancer, patients perceived treatment as being more urgently necessary than did general practitioners. Annual bowel screening might therefore be very reassuring for this particular group of patients who were initially indicated as being at high risk for bowel cancer because of their family history, even though the genetic test results proved differently afterwards, and even if the genetic test results were understood correctly. Awareness of these processes might help genetic counselors to better support their clients.
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